News Archive

2021

April

Media Release / Apr 23, 2021

Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasis

Read More
Media Release / Apr 16, 2021

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read More
Media Release / Apr 16, 2021

Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis

Read More
Media Release / Apr 12, 2021

Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Read More

March

Media Release / Mar 17, 2021

Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™

Read More

February

Media Release / Feb 16, 2021

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Read More

January

Media Release / Jan 15, 2021

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)

Read More
2020

December

Media Release / Dec 15, 2020

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF

Read More
Media Release / Dec 09, 2020

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer

Read More
Media Release / Dec 08, 2020

Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial

Read More

Related Links